EA Pharma Co., Ltd.

EA Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”) will give Poster presentations of data on EA Pharma’s originated and developed inflammatory bowel disease treatment (Development Code EA1080) in Digestive Disease Week (DDW), May 18-21, 2024, Virtual Event.

EA1080 is an orally available and small molecular selective antagonist of α4β7 integrin. In inflammatory bowel disease, lymphocytes and other inflammatory cells excessively coagulate and invade into the inflamed site. The series of reactions are mediated by binding of integrins expressed on the surface of inflammatory cells to adhesion molecules (MAdCAM-1, etc.) excessively expressed on endothelial cells in the intestinal mucosa. EA1080 can selectively antagonize α4β7 integrin to inhibit cell adhesion mediated by binding to MAdCAM-1, which suppresses invasion of lymphocytes into the inflamed site to exert anti-inflammation effects.

　In DDW 2024, EA Pharma is scheduled to present EA1080 PI clinical study data (Abstract No. 4031094).

＜Study Data to be presented＞

As a gastrointestinal specialty pharma, EA Pharma strives to create innovative pharmaceuticals to increase treatment options for patients with inflammatory bowel disease, aiming to contribute to QOL(quality of life) of patients and their families.

《More Information》

1．About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year’s history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma Co., Ltd., is a gastrointestinal specialty pharmaceutical company with a full value chain covering R&D, production & logistics and sales & marketing.
For further information on EA Pharma Co., Ltd., please visit https://www.eapharma.co.jp/en/

2．About inflammatory bowel disease (IBD)
Inflammatory bowel disease is a group of diseases that include ulcerative colitis (UC) and Crohn’s disease (CD). In these diseases, ulcers are formed in the intestinal mucosa. The major symptoms of IBD include abdominal pain, diarrhea and bloody stools. In many cases, the “remission” stage where the symptoms improve and the “relapse” stage where the symptoms deteriorate repeat over time, and patients suffer from the decline of QOL. The mechanism of onset is unknown up to the present. In Japan, IBD is one of the “designated intractable disease” by Ministry of Health, Labour and Welfare. The registered patient number amounts to about 220,000 of UC and about 70,000 of CD in Japan in 2019. The number of patients suffering from IBD has a tendency to increase in recent years.¹⁾。

Source

1) “Basic treatment guidance for patients with ulcerative colitis” (revised March 2020), “Basic treatment guidance for patients with Crohn’s disease” (revised March 2020), both edited by Research group for intractable inflammatory bowel diseases, Research project on rare and intractable diseases, Health and Labour Sciences Research Grants.